Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis

Objectives. A probabilistic model was developed to determine the cost-effectiveness of three biologics, etanercept, infliximab and adalimumab, compared with palliative care for the treatment of active and progressive PsA in patients who have an inadequate response to standard treatment (including DMARDs). Methods. A previous model was revised to evaluate the impact of biologics on both skin and joint disease and to include new evidence from the...